The company said it would also explore combinations of BNT327/PM8002 and its antibody-drug conjugates (ADC ... The move ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

As of Sept. 30, 2024, Prothena had $520.1 million in cash, cash equivalents and restricted cash, and no debt. Prothena is evaluating PRX012 — a wholly owned investigational next-generation ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and ... advanced breast cancer treated in the Phase 1 dose escalation of SYN-27M/IMM27M and ...

The trials will assess the bispecific antibody in combination with chemotherapy ... The main difference is BNT327 targets ...

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support ...